Latest Strategic Partnership News

Beacon Minerals has kicked off its first-ever drilling campaign at the Lady Ida - Lizard Project, aiming to define a maiden resource in the coming quarter. The program targets promising mineralisation with potential for significant extensions.

Nickel Industries reported a reduced loss after tax of $41.2 million for 2025, underpinned by steady production and strategic progress on its ENC HPAL project and sustainability initiatives.

TMK Energy Limited reveals strong pilot well results and a robust phased development plan for its Gurvantes XXXV Coal Seam Gas project in Mongolia, underpinned by independently certified resources and strategic partnerships.

Locksley Resources has initiated diamond drilling at its Desert Antimony Mine in California, aiming to expand known high-grade mineralisation and support US critical minerals supply chains.

Tinybeans Group announces a leadership reshuffle with Tracy Cho as Interim CEO and Rebecca White joining the Board, sharpening its focus on expanding in the lucrative U.S. family market.

Osmond Resources has partnered with Técnicas Reunidas to establish the European Union’s first vertically integrated rare earth production facility, aiming to reduce reliance on imports and boost local supply chains.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Norfolk Metals has confirmed the US$250,000 option payment for the Carmen Copper Project in Chile and completed the environmental impact report, setting the stage for further exploration and eventual ownership consolidation.

Genesis Energy has reported a record first-half normalised EBITDAF of NZ$307 million, underpinned by strong hydro inflows and portfolio flexibility, while announcing a $400 million equity raise to accelerate its renewable growth strategy.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Aurora Labs reported a 15% revenue decline and a 12% increase in net loss for H1 2026, yet marked a strategic breakthrough with its first defence propulsion order and a successful $5.5 million capital raise.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.